Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lintuzumab · HUM-195, HUMA-195-GELONIN

Radiopharmaceutical · Cytotoxic, directed at CD33 · developed by Actinium Pharmaceuticals

Phase 1 Most advanced trial (none active)

ATNM Developer

1 Registered trials

What is Lintuzumab?

Lintuzumab-Ac225 is an immunoconjugate of an anti-CD33 antibody carrying the radioactive isotope actinium-225. The antibody binds CD33 to deliver radiation to target cells. It is studied in refractory multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: HUM-195, HUMA-195-GELONIN
Drug type: Radiopharmaceutical
Targets: CD33
Mechanism: Cytotoxic, directed at CD33
Therapy area: Oncology
Developer: Actinium Pharmaceuticals (ATNM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: V00Y10W60W

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02998047	Phase 1	Refractory Multiple Myeloma	Terminated	ATNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Refractory Multiple Myeloma

Other drugs acting on CD33

Actinium Ac 225 Lintuzumab Phase 1 BI 836858 Phase 2/3 Lintuzumab-Ac225 Phase 1/2

More from Actinium Pharmaceuticals

131I-apamistamab Phase 2/3 Iodine I 131 Apamistamab Phase 3 Lintuzumab-Ac225 Phase 1/2

Sources

ClinicalTrials.gov NCT02998047

Updated Oct 11, 2026. Something wrong or missing? Report it on the ATNM page.

Follow ATNM, the company behind Lintuzumab

See ATNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ATNM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z